

姓名:	莊喬琳	填表日期: (YYYY/MM/DD)	2023/02/24	
單位:	內科部 一般內科	現職職稱:	主治醫師	
Email:	clchuang@vghtpe.gov.tw	連絡電話:	1170	
學歷:	國立陽明醫學大學醫學系 國立陽明大學臨床醫學研究所博士			
重要經歷:	臺北榮總腎臟科總醫師 國立陽明交通大學醫學系助理教授			
研究方向: (關鍵詞)	肝腎症候群、腎臟病、透析治療			
五年內 代表著作:	<ol style="list-style-type: none"> Huang HC, Chang CC, Pun CK, Tsai MH, Chuang CL, Hsu SJ, Huang YH, Hou MC, Lee FY. α-Adrenergic blockade prevented environmental temperature reduction-induced transient portal pressure surge in cirrhotic and portal hypertensive rats. Clin Sci (Lond). 2022 Oct 28;136(20):1449-1466. Hsin IF, Huang HC, Chang CC, Hsu SJ, Lee FY, Huo TI, Chuang CL, Hou MC, Lee SD. Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes. Clin Sci (Lond). 2018 Nov 19;132(22):2391-2405. Chuang CL, Chang CC, Hsu SJ, Huang HC, Lee FY, Huang LJ, Lee SD. Endotoxemia-enhanced renal vascular reactivity to endothelin-1 in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2018 Nov 1;315(5):G752-G761. Hsieh YH, Huang HC, Chang CC, Chuang CL, Lee FY, Hsu SJ, Huang YH, Hou MC, Lee SD. Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat. J Pharmacol Exp Ther. 2018 Nov;367(2):260-266. Li SY, Chuang CL, Lin CC, Tsai SH, Chen JY. Peritoneal-Membrane Characteristics and Hypervolemia Management in Peritoneal Dialysis: A Randomized Control Trial. Membranes (Basel). 2021;11(10):768. Huang HC, Ho HL, Chang CC, Chuang CL, Pun CK, Lee FY, Huang YH, Hou MC, Hsu SJ. Matrix metalloproteinase-9 inhibition or deletion attenuates portal hypertension in rodents. J Cell Mol Med. 2021 Nov;25(21):10073-10087. Pun CK, Huang HC, Chang CC, Chuang CL, Yen CH, Hsu SJ, Lee FY, Hou MC, Huang YH. Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats. Int J Mol Sci. 2021; 22(14): 7662. 			

8. Huang HC, Tsai MH, Lee FY, Lin TY, Chang CC, **Chuang CL**, Hsu SJ, Hou MC, Huang YH. NAFLD Aggravates Septic Shock Due to Inadequate Adrenal Response and 11 β -HSDs Dysregulation in Rats. *Pharmaceutics*. 2020; 12(5): 403.
9. Hsu SJ, Huang HC, **Chuang CL**, Chang CC, Hou MC, Lee FY, Lee SD. Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats. *Pharmaceutics*. 2020; 12(4): 320.
10. Chang CC, **Chuang CL**, Tsai MH, Hsin IF, Hsu SJ, Huang HC*, Lee FY, Lee SD. Effects of Caffeine Treatment on Hepatopulmonary Syndrome in Biliary Cirrhotic Rats. *Int J Mol Sci*. 2019; 20(7): 1566.
11. Chang CC, Lee WS, **Chuang CL**, Hsin IF, Hsu SJ, Huang HC*, Lee FY, Lee SD. Effect of ivabradine, a funny current inhibitor, on portal hypertensive rats. *J Chin Med Assoc*. 2019; 82(1): 19-24.
12. Hsin IF, Huang HC, Chang CC, Hsu SJ, Lee FY, Huo TI, **Chuang CL**, Hou MC, Lee SD. Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes. *Clin Sci (Lond)*. 2018; 132(22): 2391-2405.
13. Hsieh YH, Huang HC, Chang CC, **Chuang CL**, Lee FY, Hsu SJ, Huang YH, Hou MC, Lee SD. Nucleos(t)ide analogs do not independently influence hepatic fibrosis and portal hypertension beyond viral suppression in CBDL-induced cirrhotic rat. *J Pharmacol Exp Ther*. 2018; 367(2): 260-266.
14. **Chuang CL**, Chang CC, Hsu SJ, Huang HC, Lee FY, Huang LJ, Lee SD. Endotoxemia enhanced renal vascular reactivity to endothelin-1 in cirrhotic rats. *Am J Physiol Gastrointest Liver Physiol*. 2018; 315(5): G752-G761.
15. Hsu SJ, Tsai MH, Chang CC, Hsieh YH, Huang HC, Lee FY, **Chuang CL**, Hou MC, Lee SD. Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution. *Clin Sci (Lond)*. 2018; 132(6): 669-683.
16. Wu KC, Huang HC, Chang T, Lee WS, **Chuang CL**, Hsin IF, Hsu SJ, Lee FY, Chang CC, Lee SD. Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats. *Eur J Pharmacol*. 2018; 824: 133-139.

研究室成員： 陳億周、熊少瑜